Literature DB >> 8926489

Clinical scales for multiple sclerosis.

B Sharrack1, R A Hughes.   

Abstract

Many neurological rating scales have been suggested to assess the impact of multiple sclerosis on patients, but none has been universally accepted. The Kurtzke Extended Disability Status Scale has been the most widely used despite its imperfections. It combines disability and impairment, has moderate inter-rater reliability, and its overall score is heavily weighted toward ambulation. The Scripps Neurological Rating Scale attempts to quantify impairment as measured by the traditional neurological examination. However, this and other impairment scales lack direct relevance to patients' functional health status. The Ambulation Index and some of the quantitative upper limb dysfunction assessment methods are sensitive and reproducible, but they only measure limited aspects of the wide range of disabilities encountered in multiple sclerosis. Current scales of disability and activities of daily living, such as the Incapacity Status Scale and the Functional Independent Measure, are not sensitive to the type of change which occurs in multiple sclerosis. The relationship between abnormalities on magnetic resonance images of the brain and disability has been difficult to ascertain. Although recently developed imaging acquisition methods may demonstrate abnormalities which are more closely correlated with disability, the demonstration of prevention, stabilization or recovery from disability using clinical scales will remain the final arbiter of success in clinical trials. We suggest guidelines for an improved disability scale.

Entities:  

Mesh:

Year:  1996        PMID: 8926489     DOI: 10.1016/0022-510x(95)00261-y

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  21 in total

1.  Intrathecal effects of daclizumab treatment of multiple sclerosis.

Authors:  B Bielekova; N Richert; M L Herman; J Ohayon; T A Waldmann; H McFarland; R Martin; G Blevins
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

2.  Evaluation of an Expanded Disability Status Scale (EDSS) modeling strategy in multiple sclerosis.

Authors:  Hua Cao; Laurent Peyrodie; Olivier Agnani; Fabrice Cavillon; Patrick Hautecoeur; Cécile Donzé
Journal:  Med Biol Eng Comput       Date:  2015-09-07       Impact factor: 2.602

3.  Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.

Authors:  A M Novakovic; E H J Krekels; A Munafo; S Ueckert; M O Karlsson
Journal:  AAPS J       Date:  2016-09-15       Impact factor: 4.009

4.  Evaluating walking in patients with multiple sclerosis: which assessment tools are useful in clinical practice?

Authors:  Francois Bethoux; Susan Bennett
Journal:  Int J MS Care       Date:  2011

Review 5.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

6.  Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a).

Authors:  C M Gabriel; N A Gregson; N W Wood; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

7.  Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Amy N Packer; Gregg Blevins; Joan Ohayon; Henry F McFarland; Claus-Steffen Stürzebecher; Roland Martin
Journal:  Mult Scler       Date:  2009-09-23       Impact factor: 6.312

Review 8.  Microglia-Mediated Inflammation and Neurodegenerative Disease.

Authors:  Ling Xu; Dan He; Ying Bai
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

9.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Authors:  Bibiana Bielekova; Thomas Howard; Amy N Packer; Nancy Richert; Gregg Blevins; Joan Ohayon; Thomas A Waldmann; Henry F McFarland; Roland Martin
Journal:  Arch Neurol       Date:  2009-04

10.  A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.

Authors:  D T Wade; C A Young; K R Chaudhuri; D L W Davidson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.